• Publications
  • Influence
The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation
A protein that drives the growth of leukemia does so only when it carries a specific posttranslational modification. The chromosomal translocations found in acute myelogenous leukemia (AML) generateExpand
  • 172
  • 10
  • PDF
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.
RUNX1/AML1 is required for the development of definitive hematopoiesis, and its activity is altered by mutations, deletions, and chromosome translocations in human acute leukemia. RUNX1 function canExpand
  • 152
  • 7
Storage-Induced Damage to Red Blood Cell Mechanical Properties Can Be Only Partially Reversed by Rejuvenation
Background: The storage of red blood cells (RBC) is associated with impairment of their properties that can induce a circulatory risk to recipients. In a preceding study (2009), we reported thatExpand
  • 36
  • 3
Central nervous system involvement in indolent lymphomas.
BACKGROUND Central nervous system (CNS) involvement, a well-recognized complication of aggressive non-Hodgkin's lymphomas (NHL), has rarely been reported in indolent lymphomas. Large series haveExpand
  • 36
  • 3
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series
BackgroundErdheim-Chester Disease (ECD), a non Langerhans’ cell histiocytosis of orphan nature and propensity for multi-systemic presentations, comprises an intricate medical challenge in terms ofExpand
  • 23
  • 3
Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients
Therapy-related leukemia or myelodysplasia (t-leuk/MDS) is a serious problem that is increasing in frequency. We studied the clinical characteristics of 96 patients (pts) with a mean age of 48 years,Expand
  • 73
  • 2
A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer.
Recent studies suggest that anti-platelet agents are not equally effective in all individuals. We have developed a new method to evaluate the effect of anti-platelet drugs using the cone andExpand
  • 37
  • 2
Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Daratumumab is a promising new antimyeloma agent. We report a single center “real‐world” series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab.
  • 37
  • 2
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
Abstract The optimal tyrosine kinase inhibitor for any individual patient with chronic myeloid leukemia (CML) is not predictable. Pharmacogenetic parameters and trough levels of imatinib (IM) haveExpand
  • 29
  • 2
Age related microsatellite instability in T cells from healthy individuals
Many immune functions decline with age and may jeopardize the elderly, as illustrated, for example by the significantly higher mortality rate from influenza in old age. Although innate and humoralExpand
  • 42
  • 1